Work

Addressing critical knowledge gaps to improve and shorten multidrug-resistant tuberculosis treatment regimens in children

Year: 2018
Type: dissertation
Abstract: Introduction, rationale and literature review 1 Chapter 2The pharmacokinetics and safety of ofloxacin in children treated for drug-resistant tuberculosis 26 Chapter 3 Levofloxacin population pharmacokinetics in children treated for multidrug-resistant tuberculosis 37 Chapter 4 Clinical and cardiac safety of long-term levofloxacin in children treated for multidrug-resistant tuberculosis 53 Chapter 5 Pharmacokinetics, safety and dosing of novel levofloxacin dispersible tablets in children with exposure to multidrugresistant tuberculosis 70 Chapter 6 Linezolid for the treatment of drug-resistant tuberculosis in children: a review and recommendations 91 Chapter 7 The pharmacokinetics and safety of linezolid in children with multidrug-resistant tuberculosis 106 Chapter 8 Effect of coadministration of lidocaine on the pain and pharmacokinetics of intramuscular amikacin in children with multidrug-resistant tuberculosis: a randomized crossover trial 139 Chapter 9 The relative bioavailability of adult bedaquiline tablets suspended in water: implications for dosing in children 164 Chapter 10 Discussion, impact on policy and practice, future work and conclusions 190 References 215 Summary Multidrug-resistant (MDR) tuberculosis (TB), defined as TB disease or infection caused by Mycobacterium tuberculosis with resistance to at least both isoniazid and rifampicin, threatens global TB control, with an estimated 490,000 incident cases of MDR-TB globally in 2016.The burden of paediatric MDR-TB has been poorly characterized to date.However, recent modeling studies estimate that there are approximately 26,000-32,000 incident MDR-TB cases in children (< 15 years of age) worldwide each year.Traditionally, treatment regimens for adults and children were constructed using a minimum of four second-line antituberculosis drugs likely to be effective, including a second-line injectable medication, for up to 6 months, and a total duration of treatment of up to 18-24 months.In 2016, the World Health Organization (WHO) recommended a shortened (9-12 month) treatment regimen, which still includes an injectable drug for four months.In addition, the development and increasing use of the novel TB drugs bedaquiline and delamanid, are radically altering the MDR-TB treatment landscape, although children have lagged behind in accessing these important developments.Treatment outcomes for adults with MDR-TB have been persistently poor, with 54% successfully treated in 2014 both overall globally, and in South Africa.In contrast, treatment outcomes among children with MDR-TB are generally good, with 78-90% successfully treated under routine clinical conditions.However, current paediatric MDR-TB treatment regimens have important limitations.These current regimens remain long (9-18 months or more), which is costly and burdensome.There are also frequent adverse effects, including from the second-line injectable medications (amikacin, kanamycin, capreomycin) that cause permanent sensorineural hearing loss in up to 24% of children treated long-term.Additionally, the injectables are mainly given by painful daily intramuscular injections, resulting in trauma and distress for patients, their caregivers and healthcare providers.Therefore, it is an urgent priority to develop more optimal treatment regimens for children with MDR-TB that retain their efficacy but are shorter, more child-friendly, are better tolerated, safer and which do not require the use of an injectable medication.The purpose of this doctoral research was to address critical knowledge gaps in paediatric MDR-TB treatment, with the aim of informing more effective, safer, and more child-friendly MDR-TB treatment strategies in children.I identified critical knowledgeStellenbosch University https://scholar.sun.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W2943100523
Cites: 516
Cited by:
Related to: 10